Takeda Pharmaceutical Company Limited Takeda (NYSE: TAK) Announces Submission Of NDA For Lanadelumab In Japan Takeda Pharmaceutical Company Limited (NYSE: TAK) declared Friday that it has submitted New Drug Application (NDA) for Lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
Cara Therapeutics Cara (NASDAQ: CARA) Receives Priority Review Of NDA For KORSUVA Cara Therapeutics, Inc. [NASDAQ: CARA] and Vifor Pharma disclosed Monday that US FDA has recognized and awarded Priority Review for the NDA for KORSUVA solution for the cure of mild-to-serious pruritus in hemodialysis sufferers.
